Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.

25
Number of overlapping holdings
21.2%
% of XBI's 119 holdings also in CANC
51.0%
% of CANC's 49 holdings also in XBI
Overlap by Weight
Sector Drift (XBI minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
Company | Weight in XBI |
Weight in CANC |
Overlap | |
---|---|---|---|---|
BLUEPRINT MEDICINES CORP. | 2.5% | 2.8% | 2.5% | |
AMGEN INC | 2.3% | 2.7% | 2.3% | |
EXELIXIS INC | 2.1% | 3.9% | 2.1% | |
ABBVIE INC | 2.4% | 2.0% | 2.0% | |
BRIDGEBIO PHARMA, INC. | 1.8% | 4.3% | 1.8% |
Position Highlights (Non-Overlapping Exposures)
XBI Overweight Relative to CANC
EXACT SCIENCES CORP | 3.1% | |
NEUROCRINE BIOSCIENCES INC | 2.9% | |
NATERA INC | 2.9% | |
ALNYLAM PHARMACEUTICALS INC | 2.8% | |
UNITED THERAPEUTICS CORP | 2.7% | |
INSMED INC | 2.4% | |
VERTEX PHARMACEUTICALS INC | 2.4% | |
BIOGEN IDEC INC | 2.3% | |
MADRIGAL PHARMACEUTICALS, INC. | 2.2% | |
BIOMARIN PHARMACEUTICAL INC | 2.0% |
XBI Underweight Relative to CANC
ROCHE HOLDINGS LTD-SPONS ADR | -5.1% | |
ELI LILLY & CO | -4.8% | |
REVOLUTION MEDICINES, INC. | -4.6% | |
NOVARTIS AG | -4.3% | |
ASTRAZENECA PLC | -4.3% | |
BRISTOL-MYERS SQUIBB CO | -3.8% | |
GENMAB A/S SPONSORED ADR | -3.5% | |
ZAI LAB LTD. UNSPONSORED ADR | -3.1% | |
MERUS N.V. | -3.1% | |
NUVALENT, INC. CLASS A | -3.0% |